Nufarm Limited (NUF) Earnings Call Transcript & Summary
May 20, 2021
Earnings Call Speaker Segments
Operator
operatorGood day, everyone, and thanks for joining us on the line for Nufarm's 2021 Half Year Results Briefing. <<operator_script>> Please note that this call is being recorded today. So with that, I'll now pass things over to our first presenter, Mr. Greg Hunt. Thanks, and over to you, Greg.
Gregory Hunt
executiveThanks, Miles, and good morning to all of you. Thank you for being with us on today's call. Before we begin the presentation, please take a look at the disclaimer on Page 2, especially the part covering forward-looking statements. Here in Melbourne today, I'm joined by our new CFO, Paul Townsend, who came to Nufarm roughly halfway through this reporting period, and by Brent Zacharias, whom most of you know as our Group Executive for Nuseed — he's with us from Canada to discuss the Seed Technologies results. I'll begin today's presentation with a safety overview, followed by an update on how COVID affected our business during the period. Safety, of course, continues to be our top priority, and we've worked hard to maintain the record performance we delivered last year. I'm happy to say that several of our operations hit important safety milestones during the half. Our Pipe Road facility here in Australia was granted a 5-year unconditional operating license. Our Merak operation in Indonesia received an award from the Department of Labor for 10 years with 0 incidents. Several other sites are also nearing injury-free milestones: Raymond Road here in Melbourne, nearly 8 years injury-free; Alsip in Chicago, 4 years; Port Klang in Malaysia, 3 years, all injury free.
Gregory Hunt
executiveSo those are concrete illustrations of how we're moving forward with occupational and process safety management at our manufacturing sites. Still, it's reasonable to acknowledge that COVID's extended disruption brings fresh difficulties when it comes to sustaining safety results. To meet those difficulties, we're reshaping how we work so it fits more closely with each site's particular situation and evolving requirements. As for COVID's wider effects, our company has proven quite resilient, and I'd suggest the same holds true for the agriculture sector broadly. That said, the virus hasn't left us untouched, and everyday operations have taken several hits. Looking at financial performance for the half, the biggest effects came from supply delays along with elevated sea freight and logistics expenses. Demand for salmon has also fallen considerably, which has cut demand for and slowed sales of our omega-3 Aquaterra product. On the positive side, we achieved savings, and we held back discretionary costs like travel and promotional activity. We've likewise seen demand come back to normal levels in our U.S. turf and ornamental business as movement restrictions loosened later in the year.
Gregory Hunt
executiveWe also think that disruptions tied to COVID and risks in supply have shifted the way customers buy. What we're seeing this year is sales being secured earlier than normal, and that's pushing our earnings more toward the first half. Now moving on to the financial results. Performance in the first half has been very strong for us, building on momentum we set in the second half of 2020. Improved seasonal conditions and strong commodity prices are driving gains in volume, while tight supply conditions across the industry are helping margins recover in some segments. After 2 of the toughest years I've witnessed in my career in agriculture, I think we can now say with confidence that the headwinds of the past 2 years sit behind us. I'm happy to report that Nufarm has come out stronger, leaner and more determined to deliver on our objectives. We've produced revenue growth across all regions and in Seed Technologies, along with a sharp lift in EBITDA. Revenue rose 20%, and underlying EBITDA climbed 118% against the pro forma comparative. This strong first half result gives us a solid platform for a meaningful earnings improvement across the full year. As I said earlier, we expect earnings to be more heavily skewed toward the first half, and I'll go into that further in the outlook.
Gregory Hunt
executiveWe’re seeing better cash generation. Net working capital has moved by a step change, putting us back inside the range we target. Together with stronger earnings, that is lifting cash flow. Our balance sheet is still solid. Paul will go into more detail on that shortly. Although the half-year result is very positive and the outlook is encouraging, the Board has decided the interim dividend will stay suspended. This slide, Slide 6, breaks down how earnings recovered versus the prior year. As you can see, we achieved revenue and earnings growth across all regions and in Seed Technologies, with Australia and, pleasingly, Europe accounting for most of the improvement. In Australia, the end of the drought drove better sales volume, margin and manufacturing overheads. In Europe, the earnings recovery came from a mix of better seasonal conditions, lower input costs and reduced SG&A costs. Seed Technologies also posted double-digit growth, with a strong showing from the base seed portfolio thanks to the improved seasonal conditions, particularly in Australia. North America had a strong half relative to the general market. That said, currency translation, driven by a higher Australian dollar, has masked some of this improvement.
Gregory Hunt
executiveGrowth is coming through in every region, and I'll go into that further later on in the presentation. At this point, let me pass things over to Paul, who will walk through the financial details in greater depth.
Paul Townsend
executiveThanks, Greg, and good morning, everyone. Now just moving to Slide 8. Before we begin today, I want to remind everyone that because of the shift in our financial year-end, many of the comparative figures we'll be talking about are pro forma numbers, and a more detailed analysis of performance against the statutory comparative period can be found in the materials filed with the ASX this morning. I'd also like to point out that we've made sales of $76 million at 0 margin to Sumitomo in Latin America under the transitional supply agreement, and where appropriate, the impact of this has been excluded from our commentary and figures. As Greg outlined, it's been a very strong first half. Better seasonal conditions have lifted revenues and earnings in all regions and Seed Technologies. The performance improvement program has delivered the forecast cost savings, and better working capital management is lifting cash generation. We have seen a significant reduction in net debt and leverage, and this has flowed through to a significant reduction in financing costs. We expect external interest costs for the full year to be around $55 million to $60 million. This is lower than previous guidance due to lower net debt expectations and currency benefits on our U.S.-denominated financing costs.
Paul Townsend
executiveLosses on foreign currency exchange have likewise come down versus the prior half, which COVID-driven currency swings had hit. Depreciation and amortization came to $103 million for the period, and for the full year we anticipate depreciation and amortization of roughly $210 million. That assumes an Australian dollar-U.S. dollar exchange rate of $0.76. It is a touch below our earlier guidance, reflecting favorable currency translation. Our effective tax rate of circa 40% reflects the fact that in certain European countries we have not booked tax losses. For the full year, we anticipate the effective tax rate will be even higher, largely because earnings are skewed toward the first half. Those tax losses do remain available for the group to use in future periods. They are not recognized on the balance sheet, however. Importantly, full year NPAT is expected to come in below first half NPAT, given that EBITDA earnings are skewed to the first half along with the rising effective tax rate. Although our balance sheet is much stronger and our cash generation keeps improving, directors have determined that no interim dividend will be paid. We want to keep ensuring that we manage the balance sheet so as to create value for our shareholders, and a review of the principles guiding the company's approach to capital management will be finalized before we announce the full year results.
Paul Townsend
executiveMoving on to Slide 9. The performance improvement initiative we broadened out from the ANZ business roughly a year ago has delivered gains from projects aimed at lasting cost cuts of approximately $10 million during the half. We remain on track to achieve a run rate of $25 million in SG&A benefits by the close of this financial year, and $35 million to $40 million by the close of the next financial year, alongside the benefits we expect from shutting the 2,4-D plant in Linz and the Pipe Road insecticide and fungicide facility. On an overall basis, SG&A expenses came down by $24.5 million. That comparison includes a substantial currency translation benefit of roughly $15 million. There is also a certain impact from lower costs stemming from COVID-19 restrictions, which have curbed discretionary spending in areas such as travel, advertising and promotion. These reduced discretionary costs have in effect offset the effect of higher freight and logistic costs resulting from headwinds tied to COVID-19 as well as greater volumes. Research and development costs rose $4 million in the half. Although our R&D spend is comparatively modest, at about $20 million for the half, we are drawing on our strengthened financial capacity to start increasing this investment modestly.
Paul Townsend
executiveSeveral early-stage initiatives are already in progress alongside research organizations, among them the CSIRO, University of Queensland, and University of Liverpool in the U.K. These collaborative efforts remain largely at the lab and glasshouse testing stage, and our financial outlay is still modest. Even so, we regard this spending as a key component of our growth going forward. Moving now to Slide 10. Nufarm competes in an industry that is highly working capital-intensive, which makes diligent stewardship of net working capital essential to producing acceptable shareholder returns. Many of you know that our capacity to handle net working capital more effectively tends to be the biggest driver of extra cash generation. During 2019 to 2020, weak seasonal conditions—especially in Australia—along with disrupted supply chains in Europe caused working capital to accumulate on the balance sheet. Across the last 6 to 12 months, a substantial unwinding of that position has occurred, and the chart on the right shows that average net working capital to sales has returned to within our target of 35% to 40%, and we anticipate it will stay in that range through the full year. Yet the chart on the left also reveals that net working capital represented a net cash outflow for the company in the first half, which aligns with our usual trading pattern of building inventories and receivables during the first half.
Paul Townsend
executiveWe don’t have a pro forma comparative cash flow statement for the prior year. Still, it’s encouraging that we can report positive operating cash flow for the first half, even with the usual working capital build. Capital expenditure in the first half fell sharply to $54 million. That breaks down as roughly $15 million in property, plant and equipment and $30 million on intangibles, mainly investment in crop protection and seeds. The property, plant and equipment spend is below plan, largely because spending on Wyke has been deferred and will begin in the second half. We do expect CapEx to be weighted toward the second half this year. However, we probably will not spend all of the $180 million we had previously forecast for this year. Now turning to the balance sheet on Slide 11. As you can see, debt and leverage have moved significantly following the sale of our South American businesses on 1st of April last year. Leverage stands at 1.4x EBITDA on a rolling 12-month basis and is below our core leverage target of 1.5 to 2x, which includes leases.
Paul Townsend
executiveWe are carrying out an examination of how our capital is structured, aiming to evaluate how cost-efficient and flexible it is. Should any refinancing emerge from that examination, it would probably occur after the year-end results, depending on market conditions. The company keeps liquidity in a very strong position, with undrawn facilities at the half year-end of roughly $580 million and cash balances of about $500 million, respectively. That puts the business in a very robust position as we move forward. I'll hand you back to Greg, who will give you some further detail on how the regions performed.
Gregory Hunt
executiveThanks, Paul. So, starting with APAC — that region turned in a really strong first half. As most of you probably know, conditions have shifted over the last 12 months from an extremely dry drought to something very positive on the seasonal front. We've done a great deal of restructuring across this region over the past 5 years, and that effort has let us take advantage of the better conditions. First-half revenue rose 24%, and EBITDA climbed 107% to $68 million. Volume was the main engine behind that revenue growth, with drought-breaking rain in Australia and Indonesia fueling demand. Stronger commodity prices and tight industry supply have also generated early demand for winter cropping products. Our operations in Australia and New Zealand benefited most from the improved conditions. They posted revenue growth of 30%, and EBITDA rose 183% to $49 million. That earnings growth reflects gross profit margins recovering from a result heavily hurt by drought in 2019-2020. Our business in Asia also delivered a much stronger EBITDA result, up 24%, despite unfavorable currency movements. The main growth drivers there were higher volumes in Indonesia and lower SG&A costs. And while the outlook for APAC is positive for the second half, we think our earnings will probably be quite heavily weighted toward the first half, given the strong early demand for product, particularly in Australia.
Gregory Hunt
executiveTurning to Europe now. As many of you know, Europe has been a key area of focus for us. When we reported our full year results, we stated our belief that we had hit an earnings trough, and this result demonstrates that we have begun to leave the headwinds behind. This slide shows that revenues in local currency have risen 18%, while EBITDA has climbed 135% to EUR 75 million, which is roughly AUD 117 million. The factors behind this improvement are volume growth, reduced raw material prices for insecticides and fungicides, improved conversion costs and lower SG&A. We are achieving higher sales from the acquired portfolios, and that is helping to improve our product mix. Although separating the earnings of these portfolios from those of the rest of the business is becoming harder, we estimate they delivered over half of the earnings in this period. We have also recorded volume growth thanks to better seasonal conditions, especially in Germany, the U.K. and Eastern Europe, which suffered quite badly last year. Raw material costs for a range of insecticides and fungicides in our portfolio have come back to more normal levels, and that benefit is flowing through to margins. You may remember that Hildo Brilleman, our Regional General Manager for Europe, set out some targets for the performance improvement program in Europe at the full year result.
Gregory Hunt
executiveI'm happy to report that he's executing on those plans, with an estimated AUD 7 million of savings in the half, which keeps the region on track for full year benefits of AUD 15 million. As in Australia, we expect full year earnings in Europe to be weighted more toward the first half, since many of our customers purchased forward demand to secure product supply amid the disruptions caused by COVID. Now turning to North America. The stronger Australian dollar significantly affected the reported results in North America. This slide's chart displays earnings in U.S. dollars, and you can see we grew the top line by 14% and delivered a 32% increase in EBITDA, which was certainly a pleasing result. Top line growth has come from higher volumes right across the region. The turf and ornamental business also returned to more normal volumes as COVID restrictions eased. While we're seeing good demand, we're also seeing a lot of competition in the crop protection segment in North America. External supply chains have been challenging, and the combined impact of the February freeze and COVID disruptions has made it difficult for the entire industry to get product to customers.
Gregory Hunt
executiveWhat we're hearing back from customers indicates we're performing well. That said, some increases in selling and distribution costs do have to be absorbed, largely because of how quickly those costs have climbed. We've offset that to a degree by saving on discretionary spending thanks to COVID-related restrictions, and that has contributed to the improved earnings. April and May have generally brought favorable seasonal conditions, though at present we'd describe things as a touch dry in Western Canada. In North America this year, we anticipate earnings will again be weighted toward the second half. At this point I'll hand things to Brent to cover the results in the Seed Technologies segment. Thank you, Brent.
Brent Zacharias
executiveThanks, Greg, and good morning to everyone. In the Seed Technologies segment, revenues rose 37% compared with the March comparative period, while EBITDA came in at $37 million, well above the $17 million recorded across the same 6 months a year earlier. The main forces behind this better result were stronger sales of our hybrid seeds and larger endpoint royalties tied to FY '20 hybrid canola sales in Australia. Seed treatment sales also increased. Benefits from investment in our pipeline are showing up, as recent-year launches of improved canola, sorghum and sunflower hybrids have drawn solid grower backing. Our canola market share in Australia keeps getting stronger, and we recorded healthy gains across sorghum and sunflower segments in both the U.S.A. and South America. Logistics difficulties linked to COVID hurt our European business during the period. Given the shift in reporting periods, note that most sales from our core seeds portfolio will land in the first half. The Carinata program at Nuseed keeps progressing very favorably. Even with some harsh seasonal growing conditions in Argentina, we managed to scale production up successfully, attracting greater interest and backing from local growers who use Carinata as a cover crop and share in the downstream benefits of its potential as a nonfood biofuel feedstock.
Brent Zacharias
executiveWe're seeing considerable interest from offtake customers, and our existing agreements with Saipol make sure there's a market for both current output and volumes we'll produce in the near term. Nuseed Carinata has now been verified as best-in-class for greenhouse gas reduction two years running. Turning to the omega-3 canola platform: we had a successful commercial launch of Aquaterra with Chilean aquaculture customers, but then COVID-19 hit, which dramatically affected salmon demand—especially in the U.S., where restaurant businesses fell sharply. That has cut demand for Aquaterra, as well as for other fish feed inputs, and it has slowed the growth of our volumes. Because of these effects, we no longer anticipate delivering an EBITDA-positive contribution from omega-3 canola in this current financial year. Importantly, feedback from customers about their experience using Aquaterra has been very positive, and additional customers have placed orders over the period. That gives us strong confidence demand will build steadily as the market recovers. We currently hold enough stock to meet our demand forecast for the coming year, and we've decided to pause commercial planting this year while end-market conditions improve. On a positive note, the first human clinical trial of a plant-based omega-3 source was completed during the first half, showing that our product, Nutriterra, is safe and significantly raises omega-3 levels in humans.
Brent Zacharias
executiveThe trial's results showed that participants who took Nutriterra omega-3 dietary supplements absorbed the oil's long-chain omega-3s easily — DHA, EPA, and short-chain ALA — and these were incorporated into blood lipids, red blood cells included. Those findings support our commercialization plans for Nutriterra, and industry interest has reached an encouraging level. Now I'll turn things back over to Greg.
Gregory Hunt
executiveThanks, Brent. I want to underscore our conviction that the near-term hit to Aquaterra demand from COVID does not weaken, in any respect, our faith in the long-term value drivers behind this technology. So ahead of turning to the full-year outlook, let me restate our priorities. Our strategy has not changed. The financial priority continues to be better cash generation and returns. We are increasing volumes to build scale and our global footprint. We are lifting margins by widening our portfolio and product mix, putting investment into supply chain efficiency and cutting our cost base. Through the divestment of the South American operations, we have refocused the business on those regions where we think the strongest cash flows can be produced. In the end, what we are focused on is better returns. Stronger earnings from the asset base we already have will lift returns over the short term, and discipline when it comes to new investment will lift returns in the future. Now on to the outlook for the full year. Looking at the industry, we are seeing positive dynamics in the ag sector. Crop prices are strong, and relatively low end-use stocks for key commodities are shoring up grower confidence. Spending on crop inputs is robust.
Gregory Hunt
executiveNufarm stands to gain from these dynamics. By capturing share in certain segments we prioritize, we are producing growth beyond what the market delivers. Additional gains are coming from our performance-improvement program, which affords us a bit of freeboard to soak up unforeseen headwinds. A far stronger foundation is being built to underpin the earnings recovery in Europe. Our cost base is more efficient now. Supply chain efficiency is on the rise, and customers are giving us solid backing for our differentiated, higher-value products. Leverage is coming through from improved seasonal conditions, especially in Australia, and in North America our market share keeps climbing, with a good second half anticipated there, assuming supply conditions do not deteriorate materially. Following the shift in our financial year-end, the seeds business now generates the bulk of its earnings during the first half. Good growth is already locked in, and the slower ramp-up in omega-3 is not anticipated to materially affect earnings this year. In this half we have achieved a step change in our net working capital performance-to-sales ratio. For the full year, we would expect to remain within our target range of 35% to 40%.
Gregory Hunt
executiveOur attention stays squarely on the main goals: expanding volumes and revenue, lifting margins, producing additional cash, and securing better returns for shareholders. To sum up, the first half has produced a really robust result. April and May have kept up the favorable trend. Even so, our full-year outlook expectations are unchanged, since we think earnings will carry substantially more weight in the first half. So, Miles, I'll return the floor to you for some questions.
Operator
operator<<operator_script>> Today's initial question is from Grant Saligari of Credit Suisse.
Grant Saligari
analystIf I may ask a couple of questions, Greg. I suppose what I'm genuinely attempting to do is grasp the outlook statement in light of what looks like a very strong first-half result — and not merely the headline figures, but also several of the underlying gains you mentioned. So let me raise a few points with you. Looking back at your 6 months to 30th of September 2020, a pro forma figure, you produced EBITDA of $138 million. Your remark about an NPAT loss in the second half, or that full-year NPAT would probably fall below the first half, seems to suggest that second-half EBITDA won't be much stronger than that pcp full year. And with the scale of improvements you've driven through the business, that's rather difficult to grasp. So in that light, I was wondering whether you could give us a clearer picture of any revenue pull-forward you may have experienced, or other mitigating factors, other offsets, that you expect might come through in the second half, please.
Gregory Hunt
executiveYes. Thanks for asking, Grant. Look, I want to make it clear that we aren’t providing guidance. As I mentioned, our expectation for the full year is unchanged. We’re very heavily weighted toward the first half. And I might let Paul try to answer your questions that get to the heart of NPAT for the second half.
Paul Townsend
executiveYes. So, at a high level, the rationale behind that statement is this: if you look at the D&A outlook, so to speak, for the full year that I gave, and likewise the full year outlook for interest, and you consider those 2 figures in the second half, then effectively you've got $100 million of depreciation and amortization flowing through in the second half and, let's say, circa $30 million of interest costs, which makes $130 million. On top of that, you've also got an effective tax rate that's increasing. And the reason for that is that because earnings are skewed to the first half in Europe, the losses you have in the first half get larger in the second half as a result of the D&A and interest charge in that second half. So that produces a higher effective tax rate. So those 2 things lead to -- and when you take our expectations of what the full year outlook is, we feel like we'll arrive at the end result where you end up with an NPAT loss for the second half.
Gregory Hunt
executiveAnd Grant, maybe I can add a bit of context on Europe there. When you look at the information we've provided on Slide 14, it does appear to be a pretty strong — well, it is a pretty strong result for the first half. Some of that has definitely come from channel restocking in Europe. It's difficult to quantify. That said, volumes are higher, and that shows up in the improved seasonal conditions. We also have a better product mix, and that's affecting earnings from the acquired portfolio, along with better recoveries at the plants and the advantage of lower raw material costs, especially in those key fungicide products we mentioned earlier, plus you get the benefit of the $7 million reduction in performance improvement costs. And I'm sure you'd also note that we have a one-off gain on the German rebate, which, if I remember correctly, came to roughly $9 million. But I think one of the main factors really was last year's seasonal conditions. And I think a useful way to frame what we're seeing on the seasonal side in Europe right now is that it's probably closer to what we saw in financial year '19. I hope that's helpful.
Grant Saligari
analystMay I pose a follow-up? Just a quick clarification, really. On your tax remark — I'm struggling with it, because working backward from the figures you gave, if PVT is 0, then presumably the tax rate makes no difference, no additional deduction applies, and the tax is already signed off. So your comments about the tax impact are somewhat difficult for me to follow. And on tax, my question would be: what is happening in Europe, where you have stranded tax credits that you cannot use despite the strong results you have now posted across Europe? You said these are in fact prior-period tax losses that you have claimed. Some clarification on that would be helpful, please.
Paul Townsend
executiveYes. Look, without walking you through the European tax regulations and the arithmetic behind it, what I would say is this: if your earnings — just consider the following — if you earn more during the first half than you do in the second half — and I mean EBITDA prior to depreciation, amortization and interest — but your depreciation, amortization and interest are distributed more evenly, then a skew is inevitable. So then, if you have — let's suppose you have a modest loss in the first half, that loss is going to grow larger in the second half. And as a result, you can't book that loss and treat it, so to speak, as a credit, since the loss cannot be recognized. That explains why — so you end up with a bigger loss than you had in the first half. What causes losses to become stranded? We are attempting, so to speak, to plan our tax position as efficiently as we possibly can. That said, there are clearly transfer pricing rules that we have to comply with. One of the measures we're taking is that, for instance, one of the positive developments we see, where we see an improvement, is that, for instance, we have shut down the Linz facility.
Paul Townsend
executiveWe said we're closing the 2,4-D plant in Linz — and since our competitiveness is at stake there, and Linz is, of course, in Austria, we think those tax losses will turn around because we won't be in that competitive position. So that's one factor. There are other factors in Germany, and this cuts both ways, good and bad. On the positive side, when we acquired Century and Surf, we obtained an outright deduction for the purchase price, even though it's spread across many years. So from a tax planning standpoint, we can write off the entire acquisition price. But the effect of that is it actually pushes Germany into a loss position while Europe keeps improving. That fact alone produces a loss that can't be recognized, even though it can be carried forward to later years as Europe gets better and Germany gets better. So those are a couple of the reasons why the losses are what they are, and why we hold the view we do on recoverability, so to speak.
Operator
operatorRichard Johnson with Jefferies is our next caller, with a question coming through now.
Richard Johnson
analystGreg, could I begin by asking about your supply chain setup and get a read on how confident you are in all of it, given how tight markets are right now? Specifically, if you had today's market conditions that you're benefiting from a year ago, would you still have made those same changes to your manufacturing footprint that you're carrying out now?
Gregory Hunt
executiveRichard, in brief, yes — the primary shift involved 2,4-D in Europe. That facility gives us output of roughly 12,000 tonnes. Europe's market amounts to approximately 3,000 tonnes. From Linz, we were largely shipping into the Americas, and that location really isn't the right base for such activity. As for the insecticide/fungicides business here in Australia, producing either straight from China or via our Indonesian and Malaysian operations costs substantially less than doing so in Australia. So, to put it briefly, the decisions we took would not have been different.
Richard Johnson
analystUnderstood — that’s quite useful. Then would I be correct to think that when you talk about top-line growth, it has mostly come from volume instead of price? I’d also be curious to hear your perspective on what industry pricing is currently doing, especially, again, considering how tight markets are.
Gregory Hunt
executiveSee, the main driver there is volume. In Australia, we're getting some price increases since the market has been fairly tight. Still, most of it ties back to volume.
Richard Johnson
analystAll right, that's helpful. Now, regarding how you handle budgeting — what's different this time around at year-end? Has it introduced more internal complexity for you, or has it had no impact whatsoever? I'm only trying to understand whether the way you look ahead — do you still need to find the right cadence, just as we do?
Paul Townsend
executiveWell, I think it works like any budgeting process—you simply move the timing up. The prices themselves stay the same; only when things happen shifts.
Richard Johnson
analystAll right, that's great. And Paul, since I have you here, could you speak a bit about the cash tax? Going forward, how should we be thinking about it?
Paul Townsend
executiveYes. On cash tax, we anticipate paying somewhat more in the second half than in the first. The first half, I believe, comes to roughly $10 million. Our forecast is somewhere in the region of $25 million to $30 million. That figure, though, leaves out certain clean-up taxes tied to the Lat Am sale, amounting to approximately $5 million, which we are also paying during the second half. As a result, our cash tax outflow in the second half will be roughly $25 million greater. So that is — but as I mentioned, a portion of it will be the clean-up of cash taxes connected with the Lat Am sale.
Richard Johnson
analystThat’s really useful. And then last thing on tax — sorry to keep going on about it. I mean, how should we think about the tax rate past this year? I mean, how confident are you that you can bring it down?
Paul Townsend
executiveYes. Look, I think, as I mentioned, I'm getting lots and lots of questions on this, so I'll return to the tax rate. So I'm fully ready for that. I think, look, as I said before, with Europe's performance getting better, you'll see that the European tax, if you will, the tax losses in Europe will begin to shrink, which means the effective tax rate will decrease. But we expect it to — to decrease somewhat next year but not to sort of normalize for another year or so. But certainly, it's in our sights to try and figure out as best we can how to get it down to a more normalized position.
Richard Johnson
analystThanks. One final question from my side. Is Brent still on the line? Given what he said about demand, I would simply be interested to hear how fish oil prices have been trending lately.
Brent Zacharias
executiveYes. Fish oil pricing has really been fairly steady. As you're aware, it comes down to both demand and supply. So lately, a pretty sizable quota has been announced for the Peruvian catch. They're carrying that out right now. And honestly, I think we'll have to wait and watch for another 2, 3 months to get a sense of how supply looks from that catch. Then where demand is concerned, I'd note that the Chilean market has shown a more dramatic impact, while the Norwegian market has probably done a little better when it comes to the aquaculture salmon business. So I think we'll see what we're forecasting as a fairly normalized year for fish oil pricing. We don't expect much volatility in it unless they run into any problems with the catch.
Operator
operatorThe next question comes from Alex Karpos at Goldman Sachs.
Alex Karpos
analystIs this coming through okay?
Gregory Hunt
executiveAbsolutely, I can hear you perfectly. Thanks.
Alex Karpos
analystGreat, I have a couple of questions of my own. First, let's spend a little time on Europe. This has two parts, but I was hoping for additional detail on, first, the cost-reduction initiative you have discussed. You mentioned it is progressing as planned, but could you share any further incremental insights on it, along with the timing as we move into next year? Second, regarding the supply chain, thinking about the headwinds you faced in prior years — sourcing ingredients from China and the very high prices for those ingredients — how do things compare now with what you would describe as more normalized pricing for those inputs? And what does the outlook look like for the remainder of the year?
Gregory Hunt
executiveI'll take the second part of that question first, and then Paul can address the performance improvement program. As most of you probably know, we experienced quite substantial cost-of-goods pressure on several of the main products in the portfolio we acquired — stemming more broadly from what's called the China blue sky program, which honestly, over the long term, benefits the industry, but more pointedly from the explosion that happened, if I recall correctly, roughly 18 months ago, which shut down the plant. Now that those operations are coming back online, we've seen — and continue to see — I believe we shared some details at the full year. We've kept seeing COGS on those key fungicide and insecticide raw materials decline further. And I don't anticipate that turning around. So the question for us becomes how much of that value we retain. Paul, would you like to cover the...
Paul Townsend
executiveYes. Regarding the performance improvement program, I believe we noted on Slide 9 that in Europe, during the half, we had realized $7 million in savings. And from a run-rate standpoint, we anticipate that reaching $15 million for the full year. So Europe, if you will, is tracking right in line with the targets we laid out. So we're at roughly a $15 million run rate there. As for the other SG&A benefits, once again, we expect to reach that full run rate of $25 million that we had indicated by the close of FY '21 as well. So we don't anticipate hitting $25 million in total, but we do expect to be at that full run rate. Now that, of course, leaves out COVID. Now the COVID impact that we've highlighted is roughly $10 million during this first half. Now those — we're expecting a portion of that to return in the second half. But certainly, we'll capture some of it. However, we're removing the COVID-related costs from our underlying SG&A improvement. So I just want to emphasize that point, we're excluding the COVID savings from our underlying SG&A improvement, which we're stating is a $25 million run rate by the end of this year, consistent with what we've communicated.
Paul Townsend
executiveRegarding the 2,4-D synthesis closure we mentioned, our expectation is that it will begin to materialize, if you will, in the next financial year. We are drawing down inventory through the rest of this year, so none of those benefits are expected to be achieved until the following financial year, which, as we stated, we believe would be delivered in FY '22. And in a similar vein, with the Raymond Road closure, we anticipate being out of Raymond Road by the close of this year, with the benefits flowing through in FY '22 as well.
Alex Karpos
analystAnd regarding that $10 million in COVID impacts, which are in line if I understand the slides right — would it be fair to say that the bulk of those fall in North America?
Paul Townsend
executiveNo. Sorry, but those COVID savings applied right across the board. As for what offset them on the COVID side, yes, those are somewhat — freight and logistics took a heavy hit in North America.
Alex Karpos
analystUnderstood. So that $10 million comes from cutting discretionary travel and similar items—is that correct?
Paul Townsend
executiveRight, right. So here's how I look at it: $10 million in discretionary COVID savings got offset by higher freight and logistics costs, some tied to volume and some to COVID. And the bulk of those freight effects that canceled out the COVID savings landed in North America, simply because of the supply chain disruptions and the rises in freight rates.
Alex Karpos
analystUnderstood. From the slides, I believe the phrasing was that those $10 million in savings were partly offset. So how should we think about the size of the actual COVID-related expense increases in areas like logistics and freight, among others?
Paul Townsend
executiveYeah. See, we can't say, since we aren't making any comment on that or giving an estimate, purely because of the unpredictability in the supply chain and the way it's operating right now.
Alex Karpos
analystAll right, understood. And just one more quick question. Regarding capital management, you mentioned that you're reviewing it and expect to reach a decision during this year. Do you have any initial ideas about what that might look like?
Paul Townsend
executiveSo the initial thinking really boils down to establishing some leverage principles, which we've discussed before, but I want to restate that point on leverage. We'll examine capital allocation through the lens of CapEx allocation principles — growth CapEx and return targets, and so on — and then also place a genuine emphasis on generating free cash flow and, where we have surplus cash on hand, how that will, if you like, go back to shareholders. And in reviewing various mechanisms, we're clearly considering dividend policy and share buybacks, that kind of thing. But those are the kinds of items, the usual items, you obviously consider, and we expect to give a bit more detail on those principles at the full year results.
Operator
operatorThe next question is from Alex Paton at Citi.
Alex Paton
analystSeveral of your competitors have mentioned that technical ingredient expenses are rising. I'm aware that costs for fungicides and insecticides appear fairly favorable. When it comes to herbicides, though, quite a few of them describe it as a net cost headwind for this year. Could you perhaps shed some light on what you're observing on your side, and on whether you anticipate being able to pass through in full any cost inflation you may encounter this year?
Gregory Hunt
executiveThat mainly hits North America and Australia. Some of those early price increases we couldn't pass through. But in North America, in March and April, we definitely have been able to pass them on. And as I mentioned before, in Australia we've passed them on as well. But you're right, it really centers on the 3 or 4 big herbicide products that mostly come out of China.
Alex Paton
analystUnderstood. And given the context of your industry, I’m guessing you anticipate that getting worked out at some point later this year—just checking that you aren’t left holding any inventory that carries a higher cost.
Gregory Hunt
executiveYes. Look, I'd say that for those key herbicide products, channel stocks in Australia and North America have generally been quite low. So passing it on hasn't been too difficult. So you've got low channel inventories and fairly tight supply coming out of China. So the risk of getting caught — if we can put it that way — with a large volume of inventory of those products, I think, is remote. The other thing, of course, that works in our favor is that you can use those products pretty much throughout the year, whereas insecticides and fungicides, obviously, are only used when they're needed. So the stock turns on those higher-volume commodity products are a lot higher.
Alex Paton
analystThanks. One last thing on the European regulatory phaseout of certain products. It seems you saw some upside, I believe, from those final sales — Bromoxynil among them. Looking ahead, how much in earnings will be lost as these products are phased out?
Gregory Hunt
executiveOkay, on Bromoxynil, if I recall correctly, the figure is roughly EUR 8 million. And the second one, I believe, is beta-cyhalothrin. So that makes two. But in Bromoxynil's case, we do have other herbicide products that can serve as substitutes, and for beta-cyhalothrin, an insecticide, acetamiprid — one of the products we picked up with the portfolio — functions as a pretty much direct substitute. So going forward, certainly for this year and the next couple of years, the impact will be relatively small. I think most of you would be aware that the European Union has issued a strategy document from the European Commission that contains certain statements about the intent around sustainable food production. In particular, it sets some targets for reducing pesticide use, and it sets some targets for increasing organic farming. And I think our response would align with the European Crop Protection Association, which is that we're all going to back sustainable agriculture. However, I think any initiatives need to be science-based and supported by a balanced regulatory environment. So while it's challenging — I mean, we know which products are at risk. And what I would say is that while there are some challenges, there are also some opportunities for us.
Gregory Hunt
executiveAnd of course, a number of the products we picked up through that acquisition will slot in well as replacements — that's one way to describe it — for certain items in our older lineup that carry risk.
Operator
operatorThe following question is from Jonathan Snape of Bell Potter Securities.
Jonathan Snape
analystYes. Am I coming through clearly?
Gregory Hunt
executiveAbsolutely. Coming through loud and clear. Appreciate it, Jonathan.
Jonathan Snape
analystThanks. I have one question to begin with, and then a second that goes into a bit more detail on the balance sheet. I just want to confirm I heard it right — the phaseout of those products in Europe contributed EUR 10 million, which would come to roughly AUD 15 million for first half EBITDA. Is that correct?
Gregory Hunt
executiveNo — those phase-outs will wrap up during the next 2 years.
Jonathan Snape
analystAll right, so I believe there’s a remark in there about how you benefited from phasing out certain products, which produced a better outcome, and I think that’s essentially a one-off on your slide deck.
Gregory Hunt
executiveAbsolutely.
Paul Townsend
executiveAbsolutely.
Jonathan Snape
analystRight. Did that count as material? Or was it—
Gregory Hunt
executiveNo.
Paul Townsend
executiveNo, Jonathan — it's a fairly modest increase on the revenue side.
Jonathan Snape
analystAll right, that's helpful. I'm just after a bit more granularity here, so I'll try to keep this straightforward. If I turn to your segment notes — specifically Segment Note 16 on Page 29 of the annual report — I noticed the trade finance remark you have there regarding trade payables. I'm trying to work out whether that $238 million you've drawn down is essentially an affected payable. Should I be viewing it that way — that in effect, you've been granted extended credit terms?
Paul Townsend
executiveNo, what this is would be a facility for financing receivables. Essentially, the only thing involved is that we can securitize those receivables sooner than the point at which customers would ordinarily settle them under their terms — that's the entire substance of it.
Jonathan Snape
analystThat $238 million figure — up from what I believe was $198 previously — represents roughly a $40 million increase for the half, and that would have been a benefit to your cash flow.
Paul Townsend
executiveCorrect. On top of that, you're seeing higher sales too.
Jonathan Snape
analystYes. Yes. All right. All right. And looking back, that January figure, I believe, is $232 million. But excluding Latin America, I think, per the accounts, it stood at roughly $80 million 12 months earlier. So the reduction has been fairly substantial. When you consider your average net working capital to sales ratios, and when you consider where you expect that to end up at year-end, do you foresee additional drawdown on that facility? Or does that factor into your thinking about how you'll plan?
Paul Townsend
executiveAbsolutely. Everything hinges on how sales perform. As sales grow—and growing them is our aim—the facility will expand on its own to cover those receivables that qualify. And the financing is extremely cost-effective.
Jonathan Snape
analystNo, no, no — that part I get. It’s just that, from an outsider’s perspective, with everything we’ve observed in those off-balance sheet facilities, once you have a $250 million hybrid and $230 million of pull-forward sitting in there, it looks almost as though the synthetic debt facilities remain just as large as the group debt facility even now. And when the subject is capital management, I’m trying to work out how you’re approaching the overall balance sheet financing of Nufarm going forward.
Paul Townsend
executiveYeah, at the moment there’s simply more cash on hand than debt.
Operator
operatorThere's another question waiting in the queue, and it comes from Brook Campbell at JPMorgan.
Brook Campbell-Crawford
analystYes. Going back to Europe, I’m just wondering whether you could lay out which European countries you are currently losing money in, and whether you might be able to give, perhaps, some quantification of how large that loss was during the first half.
Paul Townsend
executiveYes. What about tax loss?
Brook Campbell-Crawford
analystRight, okay. So none of the European countries are ones where you're turning some kind of operating profit.
Paul Townsend
executiveHonestly, this kind of question is better handled offline, where we can go into it thoroughly.
Brook Campbell-Crawford
analystOkay. All right. Then I'll talk to you afterward.
Operator
operatorThere's one more question waiting in the queue. I'll move right over to James Ferrier at Wilsons.
James Ferrier
analystTo pick up where Jonathan left off with his question about the debt facilities, the securitized debtors that you hold — do those sit on the balance sheet, or are they off-balance sheet?
Paul Townsend
executiveThose aren’t carried on the balance sheet.
James Ferrier
analystCorrect. So the debtor balance shown on the balance sheet doesn’t include the ones you’ve securitized.
Paul Townsend
executiveAbsolutely.
James Ferrier
analystAll right, and in the same way, regarding the trade finance facility tied to payables — for payables where you have trade finance involved, those sit off-balance sheet, is that right?
Paul Townsend
executiveYou've got that right. Yes.
James Ferrier
analystYes. All right, great. So regarding those transitional supply arrangements that you have with Sumitomo in Lat Am, could you just remind me how long that arrangement runs for, and whether you've held any discussions with your suppliers about what the arrangements might look like and whether any of your arrangements could change after that agreement ends?
Gregory Hunt
executiveJames, it really comes down to two products: 2,4-D and imidacloprid. If I remember correctly, the TSA wraps up on 31st of March 2022. Once that point is reached, well, Sumitomo is free to go out to the market and purchase those products, assuming they're able to. When it comes to 2,4-D, the registrations — not every one of them, and I couldn't say whether most are, but definitely a meaningful share of those registrations are tied to Nufarm sites. So my sense is we'd keep on supplying Sumitomo, especially where 2,4-D is concerned.
James Ferrier
analystRight, I understand. So despite the fact that those assets are no longer yours, Nufarm's name still appears on the registrations. That means, in effect, you have to be part of sourcing the actives as well as distributing them.
Gregory Hunt
executiveYou're right about that. Another point I'd make is that our ties with Sumitomo are very solid. The fact is, we purchase those kinds of products on a worldwide basis. What we've seen as procurement became more centrally directed — as we centralized it — is that combining your volumes generally gets you better pricing. My expectation is that this will be the result of the talks we're holding with Sumitomo when the TSA wraps up. Still, when all is said and done, the decision will rest with them.
Operator
operatorAnd our last question comes from Evan at UBS.
Evan Karatzas
analystLet me dig a bit deeper on Europe. That 25% EBITDA margin you posted is basically the best you've likely ever achieved there. You mentioned a couple of outliers, and clearly weather has weighed on that margin over the last few years. So I'm curious: what do you view or consider a normalized margin level for Europe going forward, and for 2H as well?
Gregory Hunt
executiveSo Evan, I think you're right — if you look at EBITDA margins of 25% for the half, clearly '20 was hit by seasonal conditions along with several other issues. That means the true comparison is really with '18 and '19. What you're seeing, then, is an improvement of 300 to 400 basis points across that span, and most of it stems from the portfolio we acquired.
Operator
operatorThat brings us to the end of the question portion, so I'll return the conference to our presenters.
Gregory Hunt
executiveWell, thank you, Miles, and I appreciate everyone joining us on the call today. To sum up, we have announced what is clearly a robust set of results. As you can plainly tell from those figures, the effort we have put in across the last few years is now providing solid leverage for us to enhance conditions. So being able to report a result this strong is genuinely pleasing, and I'm looking forward to talking with many of you in the coming days and once more when we report our full year results. Thanks to you all.
Operator
operatorThat brings us to the end of today's conference call, everyone. So thank you again for joining us today, and you're all free to disconnect now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nufarm Limited transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Nufarm Limited earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nufarm Limited or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.